National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $36m contract to develop Tetraphase’s antibiotic for respiratory disease, TP-271.

The NIAID award covers development, manufacturing, and clinical activities to position TP-271 for further development against certain biothreat agents, including Francisella tularensis and bacterial pathogens associated with community-acquired bacterial pneumonia (CABP).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company said it will be working on this contract as a sub-contractor to New York, US-based independent not-for-profit scientific company CUBRC.

Tetraphase president and CEO Guy Macdonald said Tetraphase and CUBRC share NIAID’s commitment to addressing the global concerns of bioterrorism and antibiotic resistance.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact